8-K - ETON - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

December28, 2022

Date

of Report (Date of earliest event reported)

ETON

PHARMACEUTICALS, INC.

(Exactname of registrant as specified in its charter)

Delaware	001-38738	37-1858472
(State of<br><br> <br>incorporation)	(Commission<br><br> <br>File Number)	(I.R.S.Employer<br><br> <br>Identification Number)

21925W. Field Parkway, Suite 235

DeerPark, Illinois 60010-7208

(Addressof principal executive offices) (Zip code)

(847)787-7361

(Registrant’stelephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	ETON	NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item8.01 Other Events.

On December 27, 2022, Eton Pharmaceuticals, Inc submitted the New Drug Application response for its dehydrated alcohol injection product candidate to the U.S. Food and Drug Administration.

| 2 |

| --- |

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:<br> December 28, 2022	By:	/s/ James Gruber
		James<br> Gruber
		Chief<br> Financial Officer and Secretary
		(Principal<br> Financial Officer)

| 3 |

| --- |